PainReform Announces Commencement of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery
March 14, 2023 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, March 14, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq’s Minimum Bid Price Requirement
February 07, 2023 16:05 ET
|
PainReform Ltd
TEL AVIV, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Third Quarter of 2022
November 15, 2022 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, Nov. 15, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Further Update on Manufacturing of PRF-110
November 08, 2022 08:30 ET
|
PainReform Ltd
TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides PRF-110 Manufacturing Update
October 04, 2022 09:00 ET
|
PainReform Ltd
Completed tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 TEL AVIV, Israel, Oct. 04, 2022 (GLOBE NEWSWIRE)...
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the Second Quarter of 2022
August 16, 2022 08:05 ET
|
PainReform Ltd
On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022 Completes tech transfer to CMO for manufacturing of clinical batches TEL AVIV, Israel, Aug. 16, 2022 ...
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
August 16, 2022 08:00 ET
|
PainReform Ltd
TEL AVIV, Israel, Aug. 16, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform Provides Business Update for the First Quarter of 2022
May 17, 2022 07:00 ET
|
PainReform Ltd
TEL AVIV, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of...
PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th
April 12, 2022 09:00 ET
|
PainReform Ltd
TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today...